

# Prediction of 30-day readmission for vaso-occlusive crisis in patients with sickle cell disease

**Authors:** Caroline Vuong<sup>1</sup>, Kumar Utkarsh<sup>2</sup>, Rebecca Stojancic<sup>3</sup>, Arvind Subramaniam<sup>3</sup>, Olivia Fernandez<sup>3</sup>, Tanvi Banerjee<sup>4</sup>, Daniel M. Abrams<sup>2</sup>, Karin Fijnvandraat<sup>1</sup>, Nirmish Shah<sup>3</sup>

Affiliations:

1. Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands.
2. Department of Engineering Sciences and Applied Mathematics, Northwestern University, Evanston, IL, United States.
3. Division of Hematology, Duke Sickle Cell Comprehensive Care Unit, Department of Medicine, Duke University Hospital, Durham, NC, United States.
4. Department of Computer Science & Engineering, Wright State University, Dayton, OH, United States.

**Background** Sickle cell disease (SCD) is characterized by recurrent episodes of severe pain attacks, also called vaso-occlusive crisis (VOC), and are the most common reason for hospitalization. Approximately 90% of the hospital admissions are for pain treatment and the hospital readmission rate is alarmingly high, as 30-50% are readmitted within 30 days. We previously were successful in developing machine learning models to predict pain using inpatient vital signs data as well as Apple Watch data in patients with SCD hospitalized for VOC. We now aimed to predict readmission within 30 days in patients with SCD treated for a VOC.

**Methods** Patients with SCD aged 18 years and above, who were admitted for a VOC to the day hospital or Duke University Hospital between April and June 2022, were eligible for this study. Following informed consent, demographics, SCD genotype, details from the hospitalization such as length of stay, pain scores, as well as vital signs measured per standard of care were collected from the electronic medical records including blood pressure, pulse rate, respiratory rate, oxygen saturation and temperature. Baseline vital signs during regular visits were collected 6 months before and after the hospitalization. The vital signs over the entire hospital stay were averaged and those numbers were used as the predictor values for the model. The primary outcome was readmission defined as readmission within 30 days to the day hospital and/or hospital. The predictors were used to fit 3 different machine learning classification models for the prediction of readmission: random forest, logistic regression and gradient boosting. To avoid overfitting, we only used the best four predictors which were diastolic blood pressure, pulse rate, respiratory rate and pain score. The performance of the machine learning models was evaluated using the following metrics: accuracy, precision, recall, F1 score and area under the receiver-operating-curve (AUC).

**Results** Eighteen participants with SCD were included in this study. The median age at inclusion was 30 years (IQR 22-34). The majority of the participants had SCD genotype HbSS (68%), and all were Black of African-American. There were 10 participants treated at the day hospital (56%), while the other 8 participants were admitted to the hospital with a median length of stay of 7.5 days (IQR 2.5-10). After discharge, 15 participants sought medical care at least once within 30 days (83%); 8 were hospitalized (44%), and 13 were readmitted to the day hospital (72%). This pilot study consisted of 88 vital sign data points across the 18 patients. The metrics of our best-performing machine learning model, the random forest model, were: accuracy 70%, precision 0.94, recall 0.71, F1 score 0.81 and AUC 0.61. To test how the model will perform for independent data sets, we used 5-fold cross-validation, and the cross-validation accuracy was 66% with a standard deviation of 7.7.

**Conclusion** In this pilot study, our machine learning model was able to accurately predict readmission within 30 days following discharge, with real-time vital signs data collected during clinic visits and hospital admissions in participants with SCD. Prediction of readmission may help healthcare providers identify those at high risk and allow considerations for inpatient and outpatient strategies for patient management. Our next efforts include prediction of readmission from data collected from consumer wearables and in a larger number of participants.